Substituted aminopyrimidine compounds and methods of use
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not limited to leukemias and solid tumors, in mammals, especially humans.
1. A compound having Formula (I):
or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof, wherein:
X is C 3 -heterocyclyl or 5-6 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3, 4, or 5 R 1 groups;
Y is
wherein Y is optionally substituted by 1, 2, or 3 R 2 groups;
each R 1 is independently H, —C(═O)NH 2 , (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl or -(C 1 -C 4 )alkylene-OR a ;
each R 2 is independently H, F, Cl, Br, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, phenyl, or 5-membered heteroaryl, wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, phenyl, and 5 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from F, Cl, Br, —OR a , or (C 1 -C 6 )alkyl;
each R 3 and R 4 is independently H or (C 1 -C 4 )alkyl; and
each R a and R b is independently H or (C 1 -C 6 )alkyl.
2. The compound according to claim 1 , wherein X is a monovalent heterocyclyl or heteroaryl group derived from one of the following structures:
and wherein X is optionally substituted by 1, 2, or 3 R 1 groups.
3. The compound according to claim 1 , wherein Y is
and wherein Y is optionally substituted by 1 or 2 R 2 groups.
4. The compound according to claim 1 , wherein each R 1 is independently H, —C(═O)NH 2 , (C 1 -C 3 )alkyl or (C 3 -C 6 )cycloalkyl; and each R 2 is independently H, F, Cl, (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, or phenyl, wherein each of the (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, and phenyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from F, OR a , and (C 1 -C 3 )alkyl.
5. The compound according to claim 1 , wherein each R 3 and R 4 is independently H or (C 1 -C 3 )alkyl.
6. The compound according to claim 1 , wherein each R a and R b is independently H or (C 1 -C 3 )alkyl.
7. A compound having one of the following structures:
or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt or a prodrug thereof.
8. A pharmaceutical composition comprising the compound according to claim 1 , and one or more pharmaceutically acceptable carriers, excipients, diluents, adjuvants, vehicles or a combination thereof.
9. The pharmaceutical composition according to claim 8 further comprising one or more therapeutic agents.
10. A method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a therapeutically effective amount of the compound according to claim 1 , to a patient in need thereof, wherein the disorder is hematologic malignancy.
11. A method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering the pharmaceutical composition according to claim 8 , to a patient in need thereof, wherein the disorder is hematologic malignancy.
12. A method of modulating the activity of the PI3-kinase, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to claim 1 .
13. The method of claim 12 , wherein the PI3-kinase is PI3Kδ.
14. A method of modulating the activity of the PI3-kinase, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 8 .
15. The method of claim 14 , wherein the PI3-kinase is PI3Kδ.
16. A pharmaceutical composition comprising the compound according to claim 7 , and one or more pharmaceutically acceptable carriers, excipients, diluents, adjuvants, vehicles or a combination thereof.
17. The pharmaceutical composition according to claim 16 further comprising one or more therapeutic agents.
18. A method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a therapeutically effective amount of the compound according to claim 7 , to a patient in need thereof, wherein the disorder is hematologic malignancy.
19. A method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering the pharmaceutical composition according to claim 16 , to a patient in need thereof, wherein the disorder is hematologic malignancy.
20. A method of modulating the activity of the PI3-kinase, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to claim 7 .
21. A method of modulating the activity of the PI3-kinase, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 16 .